Literature DB >> 19106764

The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice.

Sudhir N Umathe1, Pravinkumar S Bhutada, Vivek S Raut, Nishant S Jain, Yogita R Mundhada.   

Abstract

Manipulation of the serotonergic system has been shown to alter ethanol sensitization. Ondansetron is a 5-HT3 receptor antagonist, reported to attenuate cocaine and methamphetamine-induced behavioral sensitization, but no reports are available on its role in ethanol-induced behavioral sensitization. Therefore, an attempt has been made to assess this issue by using an earlier used animal model of ethanol-induced locomotor sensitization. Results indicated that ondansetron (0.25-1.0 mg/kg, subcutaneously) given before the challenge dose of ethanol (2.4 g/kg, intraperitoneally) injection, significantly and dose dependently attenuated the expression of sensitization. In addition, ondansetron (1.0 mg/kg, subcutaneously) given before ethanol injection on days 1, 4, 7, and 10 significantly blocked the development (days 1, 4, 7, and 10), and expression (day 15) of sensitization to the locomotor stimulant effect of ethanol injection. Ondansetron had no effect per se on locomotor activity and did not affect blood ethanol levels. Therefore, the results raise the possibility that ondansetron blocked the development and expression of ethanol-induced locomotor sensitization by acting on 5-HT3 receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19106764     DOI: 10.1097/FBP.0b013e3283242ff4

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  5 in total

1.  Mianserin, but not ondansetron, reduces the locomotor stimulating effect of ethanol in preweanling rats.

Authors:  Carlos Arias; Norman E Spear
Journal:  Pharmacol Biochem Behav       Date:  2011-07-30       Impact factor: 3.533

2.  Neurokinin-1 receptor antagonism attenuates neuronal activity triggered by stress-induced reinstatement of alcohol seeking.

Authors:  J R Schank; B S Nelson; R Damadzic; J D Tapocik; M Yao; C E King; K E Rowe; K Cheng; K C Rice; M Heilig
Journal:  Neuropharmacology       Date:  2015-07-15       Impact factor: 5.250

3.  Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.

Authors:  Emmanuelle Simon O'Brien; Rémi Legastelois; Hakim Houchi; Catherine Vilpoux; Stéphanie Alaux-Cantin; Olivier Pierrefiche; Etienne André; Mickaël Naassila
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

4.  Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

Authors:  Bankole A Johnson; Nassima Ait-Daoud; Chamindi Seneviratne; John D Roache; Martin A Javors; Xin-Qun Wang; Lei Liu; J Kim Penberthy; Carlo C DiClemente; Ming D Li
Journal:  Am J Psychiatry       Date:  2011-01-19       Impact factor: 18.112

Review 5.  Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Authors:  Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray
Journal:  Drugs       Date:  2022-02-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.